PDS Biotechnology Corporation (NASDAQ:PDSB) price on Thursday, July 03, rose 4.72% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.33.
A look at the stock’s price movement, the close in the last trading session was $1.27, moving within a range at $1.26 and $1.34. The beta value (5-Year monthly) was 1.243. Turning to its 52-week performance, $4.42 and $0.85 were the 52-week high and 52-week low respectively. Overall, PDSB moved -13.07% over the past month.
PDS Biotechnology Corporation’s market cap currently stands at around $60.79 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-14.
Turning to the stock’s technical picture we see that short term indicators suggest on average that PDSB is a Hold. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend PDSB as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
PDSB’s current price about -14.80% and -8.07% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 41.32, while 7-day volatility ratio is 8.70% and 8.25% in the 30-day chart. Further, PDS Biotechnology Corporation (PDSB) has a beta value of 0.97. Analysts have given the company’s stock an average 52-week price target of $9, forecast between a low of $9 and high of $9. Looking at the price targets, the low is -576.69% off current price level while to achieve the yearly target high, price needs to move -576.69%. Nonetheless, investors will most likely welcome a -576.69% jump to $9 which is the analysts’ median price.
If we refocus on PDS Biotechnology Corporation (NASDAQ:PDSB), historical trading data shows that trading volumes averaged 0.48 over the past 10 days and 513.09K over the past 3 months. The company’s latest data on shares outstanding shows there are 45.45 million shares.
The 3.78% of PDS Biotechnology Corporation’s shares are in the hands of company insiders while institutional holders own 18.00% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.99 million on 2025-06-13, giving us a short ratio of 2.34. The data shows that as of 2025-06-13 short interest in PDS Biotechnology Corporation (PDSB) stood at 448.99996 of shares outstanding, with shares short falling to 2.88 million registered in 2025-05-15. Current price change has pushed the stock -56.11% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PDSB stock continues to rise going into the next quarter.
